CloTrex 50mg/tab 100 Tabletten by Concentrex Labs

Usage

1. Confirm compound clearance before starting.: Wait until the mild-cycle compound has cleared (typically 2–5 days for short-ester or oral compounds) before beginning CloTrex to avoid overlapping with active anabolic suppression.
2. Begin at 50 mg daily — one full tablet.: Take one CloTrex tablet each morning with a small meal to minimise gastric discomfort; the 50 mg dose is the appropriate opening level for mild-cycle mini-PCT.
3. Halve tablets at the start of week 3.: Use a tablet splitter to divide CloTrex tablets cleanly for the 25 mg taper phase; Concentrex Labs' compression uniformity ensures consistent half-dose results.
4. Maintain consistent daily timing.: Clomiphene Citrate has a half-life of approximately five to seven days for its active metabolites; daily dosing at the same time maintains steady-state concentrations relevant to gonadotropin stimulation.
5. Monitor subjective recovery markers during the protocol.: Libido, mood stability, and energy levels are practical indicators of axis reassertion during mini-PCT; note any persistent vision disturbances and discontinue if visual symptoms emerge.
6. Conduct a post-PCT blood panel at week six.: For mild-cycle users, a serum LH, FSH, and total testosterone panel at two weeks after protocol completion confirms whether recovery is complete or whether an additional short extension is warranted.

Warnings

Frequently asked questions

Do you actually need PCT after a mild anabolic cycle, or can you recover naturally?

Yes, PCT is still recommended after a mild cycle, though the scale is different. Even low-suppression compounds attenuate LH and FSH output sufficiently to delay natural testosterone recovery by weeks without SERM intervention. A short Clomiphene Citrate course — two to four weeks at 25–50 mg — accelerates axis normalisation, protects muscle retention during the recovery window, and prevents the prolonged low-testosterone state that mild suppression can still cause if left unaddressed.

How short can a mini-PCT with Clomiphene Citrate realistically be after a mild cycle?

A well-structured mini-PCT after a mild cycle can be as short as two to three weeks when suppression is genuinely minimal and compound clearance is confirmed. Most practitioners recommend a four-week structure at 50 mg for two weeks, then 25 mg for two weeks, as the evidence-supported minimum that allows measurable LH recovery without risking rebound. Shorter than two weeks is generally considered insufficient for reliable hormonal normalisation even in low-suppression cases.

Which SERM is considered appropriate for mild suppression — do you need the same as for heavy cycles?

Clomiphene Citrate at conservative doses is widely regarded as sufficient for mild suppression recovery, without the need to combine it with additional SERMs. Heavy-cycle protocols often layer Tamoxifen alongside Clomiphene for synergistic gonadotropin stimulation; mild-cycle users typically achieve adequate LH and FSH recovery with Clomiphene alone at 25–50 mg. CloTrex's 50 mg tablets allow both full-dose and half-dose administration, covering the full range of mild-cycle dosing needs from a single product.

Is 50 mg per tablet too high a dose for a mild-cycle PCT, and can CloTrex tablets be split?

50 mg per tablet is precisely the right starting dose for the first phase of a mild-cycle mini-PCT, and halving the tablet to 25 mg covers the tapering phase cleanly. Concentrex Labs' HPLC-verified compression consistency means each tablet contains a uniform API distribution, so splitting produces reliably proportional halves. This makes CloTrex's 50 mg format more versatile for mini-PCT protocols than lower-concentration alternatives that require multiple tablets to reach the same opening dose.

How many PCT cycles does one 100-tablet jar of CloTrex support?

A standard four-week mild-cycle mini-PCT using 50 mg for two weeks then 25 mg for two weeks consumes approximately 105 tablets — nearly one full jar per cycle. Shorter two-week protocols at 50 mg use around 70 tablets, allowing a single 100-tab jar to cover one full cycle with tablets left for a partial second run. For users who run multiple mild cycles per year, keeping one jar on hand provides a complete, single-source mini-PCT supply without mid-protocol shortfalls. (2) angle_used

Manufacturer

CloTrex occupies the ancillary position within Concentrex Labs' oral tablet catalogue — a role that places it alongside androgenic and metabolic entries in a product line unified by a single analytical release standard, but distinct from them in therapeutic purpose. Where anabolic entries in the Concentrex oral range are designed for performance-phase use, CloTrex is a recovery-phase tool, and its place in the portfolio reflects the brand's deliberate decision to build ancillary coverage into the same quality architecture that governs its anabolic products. For CloTrex specifically, that architecture requires HPLC potency verification against a certified Clomiphene Citrate pharmacopoeial reference standard at the finished-tablet stage — the same lot-level, reference-standard-anchored approach applied across the Concentrex oral line, not a category-level estimate. The practical result for the end user is that CloTrex's position as an ancillary product within a predominantly performance-oriented brand does not translate to a reduced analytical commitment; the recovery-phase tablet is held to the same release criteria as every other product bearing the Concentrex Labs name.